Stereotaxis(STXS)

Search documents
Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock
Globenewswire· 2025-07-17 12:32
Led by Strategic Industry Partner and Select Institutional InvestorsProceeds Strengthen Balance Sheet and Support Commercialization of Innovation Strategy ST. LOUIS, July 17, 2025 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has entered into definitive agreements with investors for the sale of approximately $12.5 million of its shares of common stock in a registered direct offering, a ...
Stereotaxis Reports Positive Initial Data From MAGiC Catheter Trial
ZACKS· 2025-07-07 16:55
Core Insights - Stereotaxis (STXS) announced initial clinical results for its MAGiC catheter, marking the first peer-reviewed evidence of its safety and efficacy in treating cardiac arrhythmias [1][4] - The MAGiC catheter is the first robotic, fully integrated radiofrequency ablation catheter designed for use with Stereotaxis' Robotic Magnetic Navigation system, demonstrating consistent navigation accuracy and a strong safety profile [2][4] Company Performance - Following the announcement, STXS shares remained flat, with a year-to-date decline of 3.5%, compared to the industry's 7.4% decline and the S&P 500's gain of 6.3% [3] - The company currently has a market capitalization of $189.2 million [6] Clinical Study Results - The MAGiC catheter study involved 67 patients, showing an acute efficacy rate of 94% and a low procedure-related adverse event rate of 1.5% [7][8] - The study reported no adverse events linked to catheter malfunction, with an average procedure time of 83 minutes [8] Technological Advancements - The MAGiC catheter demonstrated improved stability, steady tip temperatures during ablation, and low irrigation rates, enhancing safety and efficiency in robotic ablation procedures [9] - These advancements are expected to boost physician confidence and accelerate the adoption of Stereotaxis' robotic system [4] Industry Outlook - The global market for robotic catheterization systems is projected to grow from $54.4 million in 2025 to $190.2 million by 2035, driven by the demand for minimally invasive procedures [10][11]
Stereotaxis: Recurring Revenue Inflection
Seeking Alpha· 2025-07-06 06:13
Core Insights - Stereotaxis, Inc. (NYSE: STXS) is making significant advancements in robotic interventional cardiology while the market remains underweight on the stock [1] - The company is expected to see recurring revenue growth exceeding 25% over the next 18 months [1] Company Overview - Stereotaxis is focused on innovating within the robotic interventional cardiology space, which is gaining attention amidst the broader focus on generative AI [1] - The market perception of Stereotaxis is currently undervalued, presenting a potential investment opportunity [1] Financial Outlook - The anticipated growth in recurring revenue indicates a positive shift in the company's financial trajectory, suggesting strong future performance [1]
First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology
Globenewswire· 2025-07-01 13:00
Core Insights - Stereotaxis has published initial clinical results of the MAGiC catheter in a peer-reviewed journal, demonstrating its efficacy and safety for minimally invasive endovascular interventions [1][2]. Company Overview - Stereotaxis is a pioneer in surgical robotics for minimally invasive endovascular interventions, with a mission to develop robotic systems and solutions that enhance patient care and operating room efficiency [6]. Clinical Study Details - The study involved a prospective multi-center, single-arm design, treating 67 patients with various arrhythmias, including atrial fibrillation and ventricular tachycardia, with ongoing enrollment expected to reach around 100 patients [2][3]. - The acute efficacy of the MAGiC catheter was reported at 94%, with an average procedure time of 83 minutes and a procedure-related adverse event rate of 1.5% [3]. Product Features - The MAGiC catheter is designed for cardiac ablation procedures, enhancing treatment precision and control while maintaining safety through its soft flexible design [4]. - The catheter has shown improved stability, not requiring sheaths for support, and maintaining steady temperatures during ablation, which benefits patients with compromised cardiac and renal function [3][4]. Market Presence - Stereotaxis' robotic technologies have been utilized in over 100 leading hospitals globally, treating more than 150,000 patients [4].
Stereotaxis(STXS) - 2025 Q1 - Quarterly Report
2025-05-13 20:00
Part I: Financial Information [Item 1. Consolidated Financial Statements (unaudited)](index=4&type=section&id=Item%201.%20Consolidated%20Financial%20Statements%20(unaudited)) Unaudited Q1 2025 consolidated financial statements show increased revenue, a larger net loss, reduced cash and equity, and improved operating cash flow [Consolidated Balance Sheets](index=4&type=section&id=Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets slightly decreased, total liabilities increased, and total stockholders' equity significantly declined Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2025 | December 31, 2024 | Change | | :--- | :--- | :--- | :--- | | Cash and cash equivalents | $10,601 | $12,217 | ($1,616) | | Inventories, net | $9,812 | $8,331 | $1,481 | | Total assets | $45,705 | $46,724 | ($1,019) | | Accounts payable | $6,544 | $5,668 | $876 | | Deferred revenue (current) | $8,163 | $6,804 | $1,359 | | Total liabilities | $37,529 | $35,292 | $2,237 | | Total stockholders' equity | $2,880 | $6,080 | ($3,200) | [Consolidated Statements of Operations](index=5&type=section&id=Consolidated%20Statements%20of%20Operations) Q1 2025 operations show increased revenue driven by disposables, but higher costs and expenses resulted in a widened operating and net loss Consolidated Statement of Operations Summary (in thousands) | Metric | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Total Revenue | $7,472 | $6,880 | +8.6% | | Gross Margin | $4,064 | $3,966 | +2.5% | | Total Operating Expenses | $9,993 | $8,712 | +14.7% | | Operating Loss | ($5,929) | ($4,746) | +24.9% | | Net Loss | ($5,823) | ($4,507) | +29.2% | | Net Loss per Share (Basic & Diluted) | ($0.07) | ($0.06) | - | [Consolidated Statements of Cash Flows](index=7&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Q1 2025 cash flows show improved operating cash usage due to working capital, no investing activities, minimal financing, and an overall decrease in cash balances Cash Flow Summary (in thousands) | Cash Flow Activity | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($1,779) | ($2,346) | | Net cash provided by (used in) investing activities | $0 | $0 | | Net cash provided by financing activities | $32 | $30 | | **Net decrease in cash** | **($1,747)** | **($2,316)** | | Cash at end of period | $10,689 | $18,246 | [Notes to Financial Statements](index=8&type=section&id=Notes%20to%20Financial%20Statements) The notes detail business operations, the APT acquisition, significant accounting policies, and key risks, highlighting the company's substantial accumulated deficit - The company designs, manufactures, and markets robotic systems (Robotic Magnetic Navigation) for endovascular interventions, primarily focusing on cardiac ablation procedures for arrhythmias[24](index=24&type=chunk)[25](index=25&type=chunk) - On July 31, 2024, the company acquired Access Point Technologies EP, Inc. (APT) to gain in-house catheter development and manufacturing capabilities, involving upfront stock and contingent payments up to **$24.0 million** based on milestones[35](index=35&type=chunk)[94](index=94&type=chunk)[95](index=95&type=chunk) - The company obtained CE marking for its MAGiC catheter in Europe in Q1 2025 and is pursuing approvals in the U.S. and other regions, while the GenesisX RMN System also has CE Mark and awaits FDA clearance[38](index=38&type=chunk)[151](index=151&type=chunk) - The company faces risks from new tariffs on imports from Mexico, Canada, and China, which could increase costs, alongside ongoing supply chain disruptions, inflation, and logistics delays[42](index=42&type=chunk)[44](index=44&type=chunk)[47](index=47&type=chunk) - As of March 31, 2025, the company has an accumulated deficit of approximately **$567.5 million**, with management believing existing cash is sufficient for the next twelve months but acknowledging the potential need for additional financing[52](index=52&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=28&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q1 2025 revenue growth driven by acquisition, declining gross margin, increased operating expenses leading to higher net loss, and liquidity amidst external risks [Results of Operations](index=36&type=section&id=Results%20of%20Operations) Q1 2025 results show revenue growth from disposables offsetting systems decline, a decrease in gross margin percentage, and a significant increase in total operating expenses Revenue and Gross Margin Comparison (in millions) | Category | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Systems Revenue | $2.0 | $2.6 | -23.1% | | Disposables, Service & Accessories Revenue | $5.5 | $4.3 | +29.0% | | **Total Revenue** | **$7.5** | **$6.9** | **+9.0%** | | **Gross Margin** | **$4.1 (54%)** | **$4.0 (58%)** | **+2.5%** | Operating Expense Comparison (in millions) | Category | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Research & Development | $2.3 | $2.2 | +5.0% | | Sales & Marketing | $3.1 | $3.0 | +5.0% | | General & Administrative | $4.5 | $3.5 | +30.0% | | **Total Operating Expenses** | **$9.9** | **$8.7** | **+14.7%** | [Liquidity and Capital Resources](index=38&type=section&id=Liquidity%20and%20Capital%20Resources) As of March 31, 2025, the company maintains **$10.7 million** in cash and **$1.7 million** in working capital with no debt, believing current liquidity is sufficient for the next year despite historical losses Liquidity Position (in millions) | Metric | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents (incl. restricted) | $10.7 | $12.4 | | Working Capital | $1.7 | $4.8 | - Net cash used in operating activities decreased to **$1.8 million** in Q1 2025 from **$2.3 million** in Q1 2024, driven by changes in working capital[190](index=190&type=chunk) - The company has no debt as of March 31, 2025[193](index=193&type=chunk) [Critical Accounting Policies and Estimates](index=34&type=section&id=Critical%20Accounting%20Policies%20and%20Estimates) This section details critical accounting policies requiring significant judgment, primarily focusing on revenue recognition for multi-element contracts and stock-based compensation valuation - Revenue from contracts with multiple performance obligations is allocated based on relative standalone selling prices, which may be estimated if not directly observable[171](index=171&type=chunk) - Stock-based compensation expense is determined using valuation models (Black-Scholes for time-based, Monte Carlo for market-based awards) and is amortized over the vesting period[180](index=180&type=chunk)[181](index=181&type=chunk) [Item 4. Controls and Procedures](index=40&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls were effective as of March 31, 2025, with no material changes to internal controls, while integrating controls of the acquired business - The CEO and CFO concluded that disclosure controls and procedures were effective as of the end of the quarter[196](index=196&type=chunk) - No changes occurred during the quarter that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[197](index=197&type=chunk) - The company is currently reviewing and integrating the internal control structure of the acquired business, Access Point Technologies EP, Inc[198](index=198&type=chunk) Part II: Other Information [Item 1. Legal Proceedings](index=40&type=section&id=Item%201.%20Legal%20Proceedings) The company reports no material legal proceedings, noting a contested minor vendor dispute regarding a **$0.6 million** UCC financing statement - The company states there are no material legal proceedings[200](index=200&type=chunk) - A vendor filed a UCC financing statement on inventory for approximately **$0.6 million**, which the company is fully contesting[130](index=130&type=chunk) [Item 1A. Risk Factors](index=40&type=section&id=Item%201A.%20Risk%20Factors) This section formally states 'None,' indicating no new or materially changed risk factors are reported here compared to the prior annual filing - The report formally states 'None' for this item, meaning no new risk factors are disclosed in this section[201](index=201&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=40&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the period - There were no unregistered sales of equity securities[202](index=202&type=chunk) [Item 6. Exhibits](index=40&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including corporate governance documents, CEO and CFO certifications, and XBRL data files - The filing includes certifications from the CEO and CFO pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act[209](index=209&type=chunk) - Corporate governance documents and Inline XBRL files are included as exhibits[206](index=206&type=chunk)[209](index=209&type=chunk)
Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-05-12 22:20
Group 1: Financial Performance - Stereotaxis Inc. reported a quarterly loss of $0.07 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.06 per share a year ago [1] - The company posted revenues of $7.47 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 6.74%, and up from $6.88 million year-over-year [2] - The current consensus EPS estimate for the upcoming quarter is -$0.07 on revenues of $7.95 million, and for the current fiscal year, it is -$0.26 on revenues of $34 million [7] Group 2: Market Performance and Outlook - Stereotaxis shares have declined approximately 6.6% since the beginning of the year, while the S&P 500 has decreased by 3.8% [3] - The estimate revisions trend for Stereotaxis is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] - The Medical - Instruments industry, to which Stereotaxis belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable industry outlook [8] Group 3: Comparative Analysis - Another company in the same industry, Lucid Diagnostics Inc., is expected to report a quarterly loss of $0.09 per share, reflecting a year-over-year change of +57.1%, with revenues anticipated to be $1.3 million, up 30% from the previous year [9][10]
Stereotaxis(STXS) - 2025 Q1 - Earnings Call Transcript
2025-05-12 21:32
Stereotaxis (STXS) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants David Fischel - CEO & ChairmanKimberly Peery - CFOJoshua Jennings - Managing Director Conference Call Participants Adam Maeder - Managing Director & Senior Research AnalystFrank Takkinen - Senior Research AnalystJason Wittes - Managing Director & Senior Research Analyst Operator Good afternoon. Thank you for joining us for Stereotaxis First Quarter twenty twenty five Earnings Conference Call. Certain statements during the ...
Stereotaxis(STXS) - 2025 Q1 - Earnings Call Transcript
2025-05-12 21:30
Stereotaxis (STXS) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Speaker0 Good afternoon. Thank you for joining us for Stereotaxis First Quarter twenty twenty five Earnings Conference Call. Certain statements during the conference call and question and answer period to follow may relate to future events, expectations and as such constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and ...
Stereotaxis(STXS) - 2025 Q1 - Quarterly Results
2025-05-12 20:05
Exhibit 99.1 Stereotaxis Reports 2025 First Quarter Financial Results St. Louis, MO, May 12, 2025 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025. Revenue for the first quarter of 2025 totaled $7.5 million, a 9% increase compared to $6.9 million in the prior year first quarter. System revenue for the first quarter was $2.0 million, compar ...
Stereotaxis Reports 2025 First Quarter Financial Results
GlobeNewswire News Room· 2025-05-12 20:01
Core Insights - Stereotaxis reported a 9% increase in revenue for Q1 2025, totaling $7.5 million compared to $6.9 million in Q1 2024, driven by a 29% growth in recurring revenue [3][8] - The company is focused on advancing its innovation strategy, with key commercial advances including the initial commercialization of MAGiC in Europe and successful demonstrations of the GenesisX robot [2][8] - Stereotaxis expects double-digit revenue growth for the full year 2025, with system revenue projected at $2-3 million per quarter and recurring revenue scaling to $7 million in Q4 2025 [8][9] Financial Performance - System revenue for Q1 2025 was $2.0 million, down from $2.6 million in Q1 2024, while recurring revenue reached $5.5 million, up from $4.3 million [3][13] - Gross margin for Q1 2025 was 54%, with recurring revenue gross margin at 68% and system gross margin at 15% [4][14] - Operating loss for Q1 2025 was ($5.9) million, compared to ($4.7) million in Q1 2024, with adjusted operating loss at ($2.7) million [6][14] Cash and Liquidity - As of March 31, 2025, Stereotaxis had cash and cash equivalents of $10.7 million and no debt [7][15] - The company anticipates reduced cash use in 2025 compared to 2024, supported by growing recurring revenue and stable operating expenses [9] Regulatory and Market Outlook - Stereotaxis is advancing multiple regulatory efforts with six active reviews and plans for additional submissions, aiming for significant adoption of GenesisX pending regulatory approval in the U.S. [2][8] - The company expects substantial growth in 2026, supported by anticipated regulatory milestones and initial commercial launches in 2025 [8]